ArticleBiotechnology for biofuels2017
CRISPR-Cas9-enabled genetic disruptions for understanding ethanol and ethyl acetate biosynthesis in
Article in Biotechnology for biofuels, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 125 citations in OpenAlex.
- Yeast species resource exploration and application in cell factories.Synthetic and systems biotechnology · 2026Review
- Development of a CRISPR/Cas12a genome editing toolbox inSynthetic and systems biotechnology · 2026Article
- Molecular adaptations and engineering of extremophiles for synthetic biology and biotechnological applications.Frontiers in microbiology · 2026Review
- Analyzing the effect of glucose availability on the ethyl acetate production by Kluyveromyces marxianus under iron limitation conditions by metabolic flux analysis approach.World journal of microbiology & biotechnology · 2025Article
- PYR1 Biosensor-Driven Genome-Wide CRISPR Screens for Improved Monoterpene Production inACS synthetic biology · 2025Article
- A Study on the Extraction, Fermentation Condition Optimization, and Antioxidant Activity Assessment of Polysaccharides Derived fromFoods (Basel, Switzerland) · 2025Article
- Gene disruption via a transient hypercompact CRISPR-AsCas12f1 system in Kluyveromyces marxianus.Biotechnology letters · 2025Article
- Unravelling fungal genome editing revolution: pathological and biotechnological application aspects.Archives of microbiology · 2025Review
- Revealing Non-Conventional and Thermotolerant Yeasts from Tropical Regions: Diversity and Potential Traits for Bioproducts.Mycobiology · 2025Review
- In situ Product Recovery of Microbially Synthesized Ethyl Acetate from the Exhaust Gas of a Bioreactor by Membrane Technology.Engineering in life sciences · 2024Article
- Efficient and markerless gene integration with SlugCas9-HF in Kluyveromyces marxianus.Communications biology · 2024Article
- Engineering a carbon source-responsive promoter for improved biosynthesis in the non-conventional yeastMetabolic engineering communications · 2024Article
- Unlocking the potential ofFrontiers in microbiology · 2024Article
- Utilization of delactosed whey permeate for the synthesis of ethyl acetate with Kluyveromyces marxianus.Applied microbiology and biotechnology · 2023Article
- Prospects of thermotolerant Kluyveromyces marxianus for high solids ethanol fermentation of lignocellulosic biomass.Biotechnology for biofuels and bioproducts · 2022Article
- RNA polymerase II-driven CRISPR-Cas9 system for efficient non-growth-biased metabolic engineering ofMetabolic engineering communications · 2022Article
- Protocols for marker-free gene knock-out and knock-down in Kluyveromyces marxianus using CRISPR/Cas9.FEMS yeast research · 2022Article
- RNA Pol III promoters-key players in precisely targeted plant genome editing.Frontiers in genetics · 2022Review
- A repackaged CRISPR platform increases homology-directed repair for yeast engineering.Nature chemical biology · 2022Article
- BioprospectingFrontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe thermotolerant yeast
resultsEnabled by the design of hybrid RNA polymerase III promoters, this work adapts the CRISPR-Cas9 system from
conclusionsNewly designed RNA polymerase III promoters for sgRNA expression in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.